Steini,Mann beef (sound familiar? ) own a bit over 10% of ALA...

Steini,

Mann beef (sound familiar? ) own a bit over 10% of ALA (through a couple of accounts). That's where their money is coming from.

The top two holders of CHM, PH and Lind, own over 20% of CHM.
As I have said, very few finance entities will even look at investing in companies like CHM due to the risk. This is due to the high money burn rate during the early drug discovery phase vs. the risk of drugs not performing. The company needs access to this line of credit to keep the pipeline moving. 4 trials hitting arms isn't cheap. The GBM extension trial will hopefully lead to a fastbtrack approval trial. This is where potential value in CHM comes from! The company can't keep progressing the pipeline if it becomes cash constrained. If the pipeline stops, your investment stops. Its really that simple.
I dont think even the magic of steini's sales could Russell up a deal where a company coffs up over the entire 100% of market cap (if needed) for a less than 50% holding. And as I have said, this amount doesn't become a target to be spent, but is on call call if needed. It ensures the pipeline progresses, which is what share holders need to happen to realise investment gains. There is $0 value in the current market cap for pipeline value. So there is massive upside potential, even with any dilution. If we get some good announcements end of year and the share price rises and potential dilution reduces.

I dont think you understand the cost of CarT drug development. I dont think you understand the risk of drug development companies. And I dont really think you have any plan.

We have to agree to disagree, I am afraid.